Speeding new antibiotics to market: a fake fix?
| dc.contributor.author | Doshi, Peter | |
| dc.date.accessioned | 2017-05-25T01:13:32Z | |
| dc.date.available | 2017-05-25T01:13:32Z | |
| dc.date.issued | 2014-03-25 | |
| dc.identifier.citation | Doshi, P. (2015). Speeding new antibiotics to market: a fake fix? BMJ 2015;350:h1453. DOI: https://doi.org/10.1136/bmj.h1453 | en_US |
| dc.identifier.uri | http://hdl.handle.net/10713/6601 | |
| dc.description | Antibiotic development may finally be picking up pace, with 11 new drugs approved in the past decade, four in 2014 alone, with the help of new legislation. But in this first installment of a series on antibiotics, Peter Doshi asks why authorities are approving drugs with little evidence they do anything to tackle the problem of antimicrobial resistance. | en_US |
| dc.description.uri | http://bmj.com/cgi/content/full/bmj.h1453?ijkey=x2Dzvf2SaccxkO9&keytype=ref | |
| dc.language.iso | en_US | en_US |
| dc.publisher | BMJ Publishing Group | en_US |
| dc.subject | qualified infectious disease product (QIDP) | en_US |
| dc.subject | fast track | en_US |
| dc.subject | drug regulations | en_US |
| dc.subject | drug efficacy | en_US |
| dc.subject | research transparency | en_US |
| dc.subject.mesh | Drug Resistance, Microbial | en_US |
| dc.subject.mesh | Anti-Bacterial Agents | en_US |
| dc.title | Speeding new antibiotics to market: a fake fix? | en_US |
| dc.type | Article | en_US |
| dc.identifier.doi | 10.1136/bmj.h1453 | |
| dc.identifier.pmid | 25814536 | |
| dc.identifier.ispublished | No | en_US |
| dc.description.uriname | Click here for the free full-text article on publisher’s website | en_US |
| refterms.dateFOA | 2019-02-19T18:15:22Z |
